Tioguanine
- Generic Name
- Tioguanine
- Brand Names
- Lanvis, Tabloid
- Drug Type
- Small Molecule
- Chemical Formula
- C5H5N5S
- CAS Number
- 154-42-7
- Unique Ingredient Identifier
- WIX31ZPX66
- Background
An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.
- Indication
For remission induction and remission consolidation treatment of acute nonlymphocytic leukemias.
- Associated Conditions
- Acute Non-Lymphocytic Leukemia, Nonlymphocytic Acute myeloid leukemia
- Associated Therapies
- -
U.K. Study Shows Most Cancer Patients Would Benefit from Pharmacogenetic Testing
Analysis of 76,805 participants' germline WGS data from the 100,000 Genomes Project revealed 62.7% had genetic changes increasing risk of adverse drug reactions with five common cancer drugs. 6–10% could benefit from dose reduction or alternative medication, potentially impacting over 14,500 patients annually in England.
Inotuzumab Ozogamicin in Pediatric Patients With Relapsed or Refractory B-Cell ALL
The review highlights inotuzumab ozogamicin's role in treating pediatric ALL, particularly R/R ALL, and evolving therapeutic options. It emphasizes the drug's FDA approval for pediatric patients, its efficacy in clinical trials, and ongoing research to improve ALL treatment strategies.
Related Clinical Trials:
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath